This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Breast cancer and POP

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A study (n=9498 incident invasive breast cancer [BC]; 18,171 matched controls) found current or recent hormonal contraceptive use linked to similarly increased BC risk, regardless of whether oral combined, POP, or injectable/implant/intrauterine device of progestogen was last used (1):

  • a relative increase of approximately 20% to 30% in breast cancer risk associated with current or recent use of either combined oral or progestagen-only contraceptives
  • when the authors combined the findings with results from previous studies, which included women in a wider age range
    • 15-year absolute excess risk of breast cancer associated with use of oral contraceptives ranged from 8 per 100,000 users (increase in incidence from 0.084% to 0.093%) for use from age 16 to 20 to about 265 per 100,000 users (from 2.0% to 2.2%) for use from age 35 to 39

Reference:

  1. Fitzpatrick D et al. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case.control study and meta-analysis. PLOS Medicine March 21st 2023.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.